Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Greenbrook Tms Inc GBNHF

Greenbrook TMS Inc. is a provider of Transcranial Magnetic Stimulation (TMS) therapy and Spravato (esketamine nasal spray) therapy in the United States for the treatment of depressive disorder (MDD) and other mental health disorders. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. The Company operates a network of outpatient mental health service centers that specialize in Treatment across the United States. It offers Treatment Centers in convenient locations to provide easy access to patients and clinicians. The Company owns and operates 133 Treatment Centers in the Commonwealths of Massachusetts, Virginia and Pennsylvania and the States of Maryland, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, and South Carolina.


OTCQB:GBNHF - Post by User

Post by Betteryear2on Sep 21, 2021 5:08pm
138 Views
Post# 33896124

Acquire Achieve TMS East and Central and US$10 M Bought Deal

Acquire Achieve TMS East and Central and US$10 M Bought Deal

 

Greenbrook to acquire 17 TMS Centers in Massachusetts, Connecticut, and Iowa

Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today that it has entered into a purchase agreement pursuant to which Greenbrook will acquire Achieve TMS East, LLC (“Achieve TMS East”) and Achieve TMS Central, LLC (“Achieve TMS Central”, and together with Achieve TMS East, “Achieve TMS East/Central”).

The Company also announced today that it has entered into an agreement to sell 1,300,000 common shares of the Company (the “Common Shares”) on a bought deal basis at a price of US$7.75 (or C$9.93)per Common Share (the “Offering Price”) to a syndicate of underwriters co-led by Stifel Nicolaus Canada Inc. (“Stifel GMP”) and Bloom Burton Securities Inc. for gross proceeds of US$10,075,000 (or C$12,909,000)(the “Offering”).

Achieve TMS East/Central Acquisition:

Achieve TMS East was founded in 2016, with a vision of increasing accessibility to TMS therapy in the New England area. Since founding its first TMS center in Northampton, Massachusetts, Achieve TMS East has grown to 14locations in the States of Massachusetts and Connecticut. In 2019, Achieve TMS East’s management team expanded its operations in the Midwest United States through the establishment of Achieve TMS Central which currently operates 3TMS centers in the State of Iowa. The acquisition of Achieve TMS East and Achieve TMS Central (the “Acquisition”) is expected to enhance Greenbrook’s position as a leading provider of TMS therapy in the United States and, following completion of the Acquisition, will add an additional 17TMS centers to the Company’s existing service delivery platform, for a total of 149TMS centers.
 

https://www.businesswire.com/news/home/20210921006106/en/
<< Previous
Bullboard Posts
Next >>